

Medicinal cannabis-based products

The Malta Medicines Authority reviews submissions and issues recommendations for activities relating to cannabis for medicinal and research purposes which go through approval processes in line with the relevant legislation, including the Drug Dependence (Treatment not Imprisonment) Act, Cap 537 of the Laws of Malta, and the Production of Cannabis for Medicinal and Research Purposes Act, Cap 578 of the Laws of Malta. Production, importation, wholesale distribution, prescribing and dispensing of medicinal cannabis-based products are subject to the relevant procedures, including licenses, approvals and permits, issued by the Superintendence of Public Health.

List of medicinal cannabis-based products which have been approved for the local market:

Product Name	Form	Cannabinoid Concentration (%w/w – for products in dried flower/granulate form; mg/mL – for products in oil/extract form)	Pack Sizes	Mode of Use
<i>Afghani*</i>	<i>Dried inflorescence</i>	<i>THC: 24% w/w CBD: <1% w/w</i>	<i>10 g</i>	<i>Inhalation</i>
<i>Aphria 22/1, Variety Bienville*</i>	<i>Dried inflorescence</i>	<i>THC: 22% w/w CBD: ≤1% w/w</i>	<i>5 g</i>	<i>Oral / Inhalation</i>
<i>Aurora 20/1</i>	<i>Dried inflorescence</i>	<i>THC: 20% w/w CBD: <1% w/w</i>	<i>10 g</i>	<i>Oral / Inhalation</i>
<i>Aurora 22/1</i>	<i>Dried inflorescence</i>	<i>THC: 22% w/w CBD: <1% w/w</i>	<i>10 g</i>	<i>Oral / Inhalation</i>
<i>BCANN oil Medical Cannabis oil Sublingual drops THC 1% CBD 28% CBD Rich</i>	<i>Sublingual drops</i>	<i>THC: 10 mg/mL CBD: 280 mg/mL</i>	<i>10 mL</i>	<i>Oral</i>
<i>BCANN oil Medical Cannabis oil Sublingual drops THC 10% CBD 10% THC/CBD Balanced</i>	<i>Sublingual drops</i>	<i>THC: 100 mg/mL CBD: 100 mg/mL</i>	<i>10 mL</i>	<i>Oral</i>

Product Name	Form	Cannabinoid Concentration (%w/w – for products in dried flower/granulate form; mg/mL – for products in oil/extract form)	Pack Sizes	Mode of Use
BCANN oil Medical Cannabis oil Sublingual drops THC 20% CBD 4% THC Rich	Sublingual drops	THC: 200 mg/mL CBD: 40 mg/mL	10 mL	Oral
Cannabis 1A 18/1*	Dried inflorescence	THC: 18% w/w CBD: ≤1% w/w	10 g	Inhalation
Cannabis Flos WEECO 25/1*	Dried inflorescence	THC: 25% w/w CBD: ≤1% w/w	10 g	Inhalation
Carbasi Verde, Cannabis Flower, Strain code: ASID 005/2019-1001*	Dried inflorescence	THC: 20% w/w CBD: ≤1% w/w	5 g; 15 g	Oral / Inhalation
Materia Dark Shadow Haze*	Dried inflorescence	THC: 28% w/w CBD: ≤1% w/w	5 g; 10 g	Oral
Materia Dark Shadow Haze Irr.*	Dried inflorescence	THC: 28% w/w CBD: ≤1% w/w	5 g; 10 g	Oral / Inhalation
Materia Vanilla Cake Irr.*	Dried inflorescence	THC: 23% w/w CBD: ≤1% w/w	5 g	Oral
Medi-Glue Intense 23/1	Dried inflorescence	THC: 23% w/w CBD: <1% w/w	10 g	Inhalation
Panaxir CBD25	Cannabis extract standardized in MCT oil	THC: ≤1.5 mg/mL CBD: 25 mg/mL	30 mL	Oral
Panaxir THC25	Cannabis extract standardized in MCT oil	THC: 25 mg/mL CBD: ≤1.5 mg/mL	30 mL	Oral

Product Name	Form	Cannabinoid Concentration (%w/w – for products in dried flower/granulate form; mg/mL – for products in oil/extract form)	Pack Sizes	Mode of Use
<i>Panaxir THC25/CBD25</i>	<i>Cannabis extract standardized in MCT oil</i>	<i>THC: 25 mg/mL CBD: 25 mg/mL</i>	<i>30 mL</i>	<i>Oral</i>
<i>Panaxir THC50</i>	<i>Cannabis extract standardized in MCT oil</i>	<i>THC: 50 mg/mL CBD: ≤0.3 mg/mL</i>	<i>30 mL</i>	<i>Oral</i>
<i>Pedarios 20/1</i>	<i>Dried inflorescence</i>	<i>THC: 20% w/w CBD: <1% w/w</i>	<i>10 g</i>	<i>Oral / Inhalation</i>
<i>Pedarios 22/1</i>	<i>Dried inflorescence</i>	<i>THC: 22% w/w CBD: <1% w/w</i>	<i>10 g</i>	<i>Oral / Inhalation</i>
<i>Salus Biopharma Medical Cannabis Flower</i>	<i>Dried inflorescence</i>	<i>THC: 20% w/w CBD: <1% w/w</i>	<i>5 g; 10 g</i>	<i>Oral / Inhalation</i>

** Products approved for batch-specific assay labelling where the cannabinoid(s) concentration might exceed the ±10% relative deviation of the stated content.*

Unit packs of products manufactured in Malta display a 10-alphanumeric serial number (e.g. 123MTXXXXX). Unit packs of products sourced to Malta display a 7-alphanumeric serial number (e.g. A111111).

All stakeholders involved in the supply chain making medicinal cannabis-based products accessible to patients shall collaborate to ensure traceability and reconciliation practices are maintained throughout; this includes keeping records of the serial numbers of unit product packs up to the dispensing stage (including at producer, importer, distributor and pharmacy level).

Updated on 18 July 2024

For further information, contact: cannabis.medicinesauthority@gov.mt or +356 2343 9273